Insmed Q1 Revenues Reach $306M with 44% BRINSUPRI Surge and TPIP Progress
INSM•Insmed reported Q1 2026 revenues of $306.0 million, led by BRINSUPRI sales of $207.9 million (up 44% Q/Q) and ARIKAYCE sales of $98.1 million (up 6% Y/Y). The company reiterated 2026 guidance for ≥$1 billion BRINSUPRI and $450–470 million ARIKAYCE, and advanced Phase 3 TPIP trials.
1. First-Quarter 2026 Financial Results
Insmed generated total revenues of $306.0 million in Q1 2026, with BRINSUPRI contributing $207.9 million, up 44% sequentially, and ARIKAYCE delivering $98.1 million, a 6% increase year-over-year.
2. Reaffirmed 2026 Revenue Guidance
The company maintained its full-year targets of at least $1 billion in BRINSUPRI sales and $450–470 million in ARIKAYCE revenues, reflecting confidence in ongoing commercial momentum and market penetration.
3. Commercial and Pipeline Developments
Key developments include MHRA approval of BRINSUPRI in the U.K., anticipated Japanese regulatory decisions for brensocatib, positive Phase 3b ENCORE results for ARIKAYCE, Phase 3 PALM-PAH study initiation for TPIP, and plans for additional Phase 3 programs through 2027.
